Prevalence and short-term outcome of acute kidney injury in patients with acute-on-chronic liver failure: A meta-analysis

J Viral Hepat. 2020 Aug;27(8):810-817. doi: 10.1111/jvh.13287. Epub 2020 Mar 18.

Abstract

Acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF) is a distinct syndrome to that in patients with cirrhosis, yet is less characterized. The aim of this meta-analysis was to investigate the impact of AKI on outcome of ACLF. We searched PubMed, Web of Science and Cochrane Library for original articles that evaluated the impact of AKI on outcome of ACLF from 2011 to 2019. Odds ratio (OR) with 95% confidence interval (CI) for 1-month and 3-month mortality was calculated. The response rate of vasoconstrictor for hepatorenal syndrome (HRS)-AKI was assessed. Eight relevant articles with 3610 patients were included. The prevalence of AKI in ACLF patients was 41% (95% CI 32%-50%). The presence of AKI was significantly associated with 1-month mortality of ACLF (OR 3.98, 95% CI 3.09-5.12; P < .001) and 3-month mortality (OR 4.98, 95% CI 3.59-6.92; P < .001). Additionally, patients with AKI stage ≥2 showed a higher 3-month mortality than stage 1 (OR 3.89, 95% CI 2.60-5.82; P < .001), and those of stage 3 had a higher mortality than stage ≤2 (OR 3.77, 95% CI 2.10-6.77; P < .001). The pooled response rate of vasoconstrictors was 32% (95% CI 26%-37%). This meta-analysis indicated that about 40% of ACLF patients complicated with AKI and the presence of AKI substantially increased the short-term mortality, together with a poor response rate of vasoconstrictors for HRS-AKI.

Keywords: acute-on-chronic liver failure; hepatorenal syndrome; kidney injury; mortality; prevalence.

Publication types

  • Meta-Analysis

MeSH terms

  • Acute Kidney Injury* / complications
  • Acute Kidney Injury* / mortality
  • Acute-On-Chronic Liver Failure* / complications
  • Acute-On-Chronic Liver Failure* / mortality
  • Humans
  • Prevalence
  • Prognosis
  • Vasoconstrictor Agents / therapeutic use

Substances

  • Vasoconstrictor Agents